Aminoglycosides only when benefits outweigh fetal ototoxicity risk (Class IIb)
Beta-lactams generally preferred when susceptible
Imaging considerations
TEE preferred over radiation-based studies when feasible
CT with shielding when life-threatening complication suspected
Obstetric involvement
Fetal monitoring in viable gestations with maternal instability
Geriatric
Geriatric considerations
Atypical presentation
Afebrile sepsis possible
Delirium as primary symptom
Renal dosing emphasis
Vancomycin and aminoglycoside toxicity risk
Frailty and goals of care
Early discussion when surgical risk high
Pediatrics
Pediatric considerations
Risk profile
Congenital heart disease prevalence
Central venous catheter association
Weight-based antibiotic dosing
Vancomycin dosing per local pediatric protocol with level monitoring
Ceftriaxone dosing per mg/kg/day targets
Echocardiography pathway
TTE often higher yield due to body habitus
TEE when nondiagnostic and suspicion high
Kawasaki disease and rheumatic fever differentiation
Consider in prolonged fever with cardiac findings
Background
Epidemiology
Epidemiologic features
Incidence range
Approximately 3-10 per 100,000 person-years in many regions
Age distribution
Increasing incidence with older age
Common risk groups
Prosthetic valves and intracardiac devices
Hemodialysis
Injection drug use
Common pathogens
Staphylococcus aureus as leading cause in many contemporary cohorts
Streptococci and enterococci common
Pathophysiology
Core mechanisms
Endothelial injury and platelet-fibrin nidus
Turbulent flow across abnormal valves
Transient or sustained bacteremia seeding
Skin, oral, or intravascular sources
Vegetation effects
Valvular destruction and regurgitation
Conduction system invasion with abscess
Septic embolization
Immune complex phenomena
Right-sided vs left-sided patterns
Right-sided
Septic pulmonary emboli
Tricuspid valve common in injection drug use
Left-sided
Stroke and systemic emboli
Heart failure from mitral or aortic regurgitation
Therapeutic Considerations
Antibiotic strategy rationale
High inoculum infection
Prolonged IV therapy required (Class I)
Biofilm considerations in prosthetic material
Rifampin adjunct in staphylococcal prosthetic infections (Class IIa)
Synergy principles
Enterococcus requires combination therapy for bactericidal effect (Class I)
Monitoring rationale
Repeat cultures until clearance
Drug level monitoring for nephrotoxic agents
Outcomes and prognostic drivers
Early surgery improves outcomes in selected high-risk scenarios (Class I)
Persistent bacteremia predicts complications and mortality
Patient Discharge Instructions
copy discharge instructions
Discharge information set
Diagnosis uncertainty statement
Concern for bloodstream infection or heart valve infection
Medications
Antibiotics only as prescribed
Avoid leftover antibiotics
Return immediately for
Worsening shortness of breath
Chest pain
Fainting
New weakness or numbness
New trouble speaking or confusion
Severe headache
Persistent fever
Repeated vomiting or inability to keep fluids down
New rash with bruising or purple spots
Follow-up timing
Urgent follow-up within 24-48 hours if discharged during evaluation
Blood culture result review plan
Harm reduction and prevention
If injection drug use, offer linkage to addiction care and safer use resources
Dental care follow-up when poor dentition identified
References
Guidelines and core sources
Key guideline set
American Heart Association scientific statement on infective endocarditis management with Class I and II recommendations
European Society of Cardiology guidelines on infective endocarditis with surgical indication criteria
IDSA guidance for bacteremia and endocarditis antimicrobial regimens
Modified Duke criteria primary source and validation literature
Evidence and practice standards
Vancomycin AUC-guided dosing consensus for serious MRSA infections
OPAT best practice recommendations for prolonged IV antibiotics
Stroke guidelines addressing infective endocarditis as thrombolysis exclusion context
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.